Did the Spanish Flu really kill 50 to 100 million people? Did the pandemic last 2 years? Was the influenza virus really the killer? Did government censorship prevent the public from hearing about a deadly disease spreading in 1918? Did everyone wear masks and were they effective? Was Philadelphia’s Liberty Loans Parade a ‘super-spreader’ event?
Media coverage of a promising Covid-19 treatment has flipped from supportive to negative, a US health official has revealed, suggesting the president’s praise of the treatment might relate to it falling out of favor.
Blood from people who recover from coronavirus could provide a treatment, reported the Washington Post on March 27, just a couple weeks after the World Health Organization declared COVID-19 a pandemic.
Just over a week later, the Washington Post reported again that while there was no vaccine yet for COVID-19, we do have one potentially promising treatment to help people infected with the coronavirus: infusions of antibody-rich plasma from other patients who have had the disease and recovered.
Imagine going to the doctor for a cough and getting a transfusion of blood from a goat. It probably sounds strange today, but that is exactly how antibody therapy started in the late 1800s.
Researchers found that plasma, the part of blood left when you get rid of the cells, had healing properties. In fact, the first Nobel Prize in physiology or medicine was awarded to Emil von Behring in 1901 for his work using this approach to treat diphtheria.
WASHINGTON – Last week, just as the Food and Drug Administration was preparing to issue an emergency authorization for blood plasma as a Covid-19 treatment, a group of top federal health officials including Dr. Francis S. Collins and Dr. Anthony S. Fauci intervened, arguing that emerging data on the treatment was too weak, according to two senior administration officials.
The bag of frozen yellow liquid doesn’t look like much, but it might have the power to help a patient survive COVID-19.
Or it might be another promising idea that doesn’t quite pan out.
The bag holds convalescent plasma, a golden elixir distilled from the blood of someone who has already recovered from a case of COVID-19.
That person donated something from their own body, hoping to help another. That same hope has inspired countless other donors, in epidemics going back more than 110 years. And the doctors who have infused that plasma into their patients have hoped that transferring its disease-fighting antibodies from a recovered person to a sick person will help.
Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality – The American Journal of Pathology
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has spread globally, and proven treatments are limited. Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 is among many approaches being studied as potentially efficacious therapy. We are conducting a prospective, propensity scorematched study assessing the efficacy of COVID-19 convalescent plasma transfusion versus standard of care as treatment for severe and/or critical COVID-19. We present herein the results of an interim analysis of 316 patients enrolled at Houston Methodist hospitals from March 28 to July 6, 2020. Of the 316 transfused patients, 136 met a 28-day outcome and were matched to 251 non-transfused control COVID-19 patients. Matching criteria included age, sex, body mass index, comorbidities, and baseline ventilation requirement 48 hours from admission, and in a second matching analysis, ventilation status at day 0. Variability in the timing of transfusion relative to admission and titer of antibodies of plasma transfused allowed for analysis in specific matched cohorts. The analysis showed a significant reduction (P = 0.047) in mortality within 28 days, specifically in patients transfused within 72 hours of admission with plasma with an anti-spike protein receptor binding domain titer of ?1:1350. These data suggest that treatment of COVID-19 with high antireceptor binding domain IgG titer convalescent plasma is efficacious in early-disease patients.
Health Feedback’s review is fatally faulty right off the top, when the review’s unnamed author mistakes my co-author Patrick Corbett for James Corbett of The Corbett Report: the screencap at the top of the review is from James Corbett’s June 16 interview with me.
May 7 (UPI) — Johns Hopkins University next week will start two clinical trials of convalescent blood plasma to treat COVID-19, the disease caused by the new coronavirus.
Researchers at the university said the trials will be focused on frontline healthcare workers and nursing home residents — two groups that are particularly vulnerable to SARS-CoV-2, the virus that causes COVID-19.
Their expectation is that the blood from recovered patients contains antibodies — or immune cells — that fight the virus and can help these patients get better.
In 1934, a doctor at a private boy’s school in Pennsylvania tried a unique method to stave off a potentially deadly measles outbreak. Dr. J. Roswell Gallagher extracted blood serum from a student who had recently recovered from a serious measles infection and began injecting the plasma into 62 other boys who were at high risk of catching the disease.